Mounzer Agha, MD, Reviews the Safety Profile of Ciltacabtagene Autoleucel in Multiple Myeloma
July 10th 2021During a discussion at ASCO 2021, Mounzer Agha, MD, talked about mitigation strategies used by the investigators from the CARTITUDE-2 trial to prevent cognitive and neuro-movement disorders commonly associated with CAR T-cell therapy.
Philippe Moreau, MD, on Results With Daratumumab Plus VTd in Newly Diagnosed Myeloma at ASCO 2021
July 8th 2021Moreau detailed the patient characteristics of those enrolled on the CASSIOPEIA trial, which investigating bortezomib, thalidomide and dexamethasone plus daratumumab in patients with newly diagnosed multiple myeloma.
Philippe Moreau, MD, on Updates in Multiple Myeloma Presented at ASCO 2021
June 25th 2021Moreau highlighted important updates in the field of multiple myeloma, including the CARTITUDE-1 trial, which yielded promising results with ciltacabtagene autoleucel and read out at the 2021 ASCO Annual Meeting.
Paul M. Barr, MD, Examines Head-to-Head Data on BTK Inhibitors in Previously Treated, High-Risk CLL
June 9th 2021CancerNetwork® sat down with Paul M. Barr, MD, at the 2021 ASCO Annual Meeting to talk about what data has the greatest potential to impact standard treatment of chronic lymphocytic leukemia.
Compared With ASCT, KCd Shows Potential Utility for Newly Diagnosed, Transplant-Eligible MM
June 8th 2021Compared to upfront autologous stem cell transplantation for newly diagnosed, transplant-eligible patients with multiple myeloma, carfilzomib consolidation with cyclophosphamide and dexamethasone produced noninferior results.
Larry Anderson, MD, PhD, Discussed Updated Results of the KarMMa Trial at ASCO
June 6th 2021CancerNetwork® sat down with Larry Anderson, MD, PhD, at the 2021 ASCO Annual Meeting to talk about updated data from the KarMMa trial of CAR T-cell therapy idecabtagene vicleucel to treat patients with relapsed or refractory multiple myeloma.